Damora Therapeutics, Inc. insider trading

DMRANASDAQ

$20.65+0.42 (+2.08%)as of Oct 2, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (+422.8%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
Date	Category	Person	Role	Action	Amount	Change in holding

Open market purchase

Open market sell

Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium

Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Unlock quarterly net flow

Key players

JJJennifer JarrettDirector, President and CEO0.8099%of company
HLHewes L. BeckerChief Medical Officer0.4287%of company
SSSherwin SattarzadehChief Operating Officer0.3084%of company
JBJulianne BrunoDirector0.222%of company
HTHans T. SchambyeChief Executive Officer0.0076%of company
GWGarrett WinslowGeneral Counsel0.0037%of company
LFLori FirmaniChief Financial Officer0.0015%of company
FHFairmount Healthcare Fund II L.P.DirectorNot reportedof company

AI Activity Analysis

Premium

Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto

Company	Insider / role	Action	ΔOwn	Avg price	Amount
DMRA	Jennifer JarrettDirector, President and CEO	Open market purchase$253K	+2.5%	$20.23	$253K	Sep 25, 2026	Sep 28, 2026
DMRA	Garrett WinslowGeneral Counsel	Open market sell$7.35K	-9.7%	$29.98	$7.35K	Jul 6, 2026	Jul 7, 2026

End of history · 2 transactions